Journal: Communications Biology

Article Title: PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19

doi: 10.1038/s42003-022-03766-2

Figure Lengend Snippet: a Groups of mice were treated intraperitoneally with PIKfyve inhibitors WX8 or NDF once daily beginning 1 day pre-intranasal-challenge with 1 × 10 5 plaque forming units SARS-CoV-2 (B.1.351). EIDD-2801 dosed twice a day was used as a positive treatment control and uninfected treatment controls were included to assess cytotoxicity. Image created using BioRender. b Weight changes were determined for 4 days post-challenge, plotted as the group mean with error bars indicating the ±SD. c Infectious viral loads from lung homogenates at 2 (black) or 4 (gray) days post SARS-CoV-2 challenge. d Lungs were collected at 2- or 4-days post-challenge and stained with hematoxylin and eosin to assess bronchiolar and alveolar damage and immune cell infiltration (500-μm scale bar shown at bottom left, representative for all panels). Mixed-effects analysis was used to compare differences in weight change or viral loads from lung homogenates between infection treatment groups and the vehicle-treated control group; ** p ≤ 0.01, **** p ≤ 0.0001. dpi, days post-infection; PO, oral dosing; IP, intraperitoneal; IN, intranasal.

Article Snippet: EIDD-2801 (150 mg/kg, WuXi AppTec) was dosed orally, twice daily, starting one day prior to infection was used as a positive control for all experiments, as it has been shown to be efficacious in animal models previously , .

Techniques: Staining, Infection

Journal: Communications Biology

Article Title: PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19

doi: 10.1038/s42003-022-03766-2

Figure Lengend Snippet: a Groups of mice were treated intraperitoneally with PIKfyve inhibitors Apilimod, WX8, or NDF once daily beginning 1 day post-intranasal-challenge with 1 × 10 3 plaque forming units SARS-CoV-2 (MA-10). EIDD-2801 dosed twice a day was used as a positive treatment control and uninfected treatment controls were included to assess cytotoxicity. Image created using Biorender. b Weight changes were determined for 4 days post-challenge, plotted as the group mean with error bars indicating the ±SD. c Infectious viral loads from lung homogenates at 2- (black) or 4- (gray) days post SARS-CoV-2 challenge. d Survival curves for treatment groups. e Lungs were collected at 2- or 4-days post-challenge and stained with hematoxylin and eosin to assess bronchiolar and alveolar damage and immune cell infiltration (500-μm scale bar shown at bottom left, representative for all panels). Mixed-effects analysis was used to compare differences in weight change or viral loads from lung homogenates between infection treatment groups and the vehicle-treated control group; * p ≤ 0.1, *** p ≤ 0.001, **** p ≤ 0.0001. dpi, days post-infection; PO, oral dosing; IP, intraperitoneal; IN, intranasal.

Article Snippet: EIDD-2801 (150 mg/kg, WuXi AppTec) was dosed orally, twice daily, starting one day prior to infection was used as a positive control for all experiments, as it has been shown to be efficacious in animal models previously , .

Techniques: Staining, Infection

Journal: bioRxiv

Article Title: Lassa virus NP DEDDh 3’-5’ exoribonuclease activity is required for optimal viral RNA replication

doi: 10.1101/2023.04.12.536665

Figure Lengend Snippet: (A). Vero cells were treated with 5’-FU and EIDD-1931 at indicated concentrations. At 48 hr post treatment, cell viability was measured using CellTiter-Glo Viability Assay (Promega). Data shown are the average (n=4) and SEM. (B) and (C). Vero cells were treated with 5-FU and EIDD-1931 at different concentrations as indicated. Cells were infected with wt rLASV (wt) and ExoN-rLASV (ExoN-) at MOI 0.1. At 48 hpi, virus titers were determined by plaque assay. Log10 virus titer changes relative to the virus titer of non-treated cells are shown. Data presented are the mean and the SEM of three independent experiments.

Article Snippet: Treatment of Vero cells with EIDD-1931 (5 µM -100 µM) alone did not substantially affect cell viability ( , CellTiter-Glo Viability Assay, Promega).

Techniques: Viability Assay, Infection, Virus, Plaque Assay